Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 4Lymphoma, Non-Hodgkin 4Cytokine Release Syndrome 4Prostatic Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Renal Cell 2Thrombocytosis 1Thrombocytopenia 1Smoldering Multiple Myeloma 1Schwannomatosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pain 1Ovarian Neoplasms 1Neurilemmoma 1Neoplasms by Histologic Type 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Large Granular Lymphocytic 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × siltuximab × Clear all
NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT01531998 2015-06-19

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

M.D. Anderson Cancer Center

Phase 1/2 Completed
14 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Centocor, Inc.

Phase 2 Completed
53 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡